个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Improved Overall Survival Associated With Decreased Distant Metastasis Following Asparaginase-Based Chemotherapy and Radiotherapy for Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma.

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ EI

作者：
Zheng X[1] * ; He X[2] ; Yang Y[1] ; Qi S N[1] ; Zhang L L[3] ; Qu B L[4] ; Zhong Q Z[5] ; Qian L T[6] ; Hou X R[7] ; Qiao X Y[8] ; Wang H[9] ; Zhu Y[10] ; Cao J Z[11] ; Wu J X[12] ; Wu T[13] ; Zhu S Y[14] ; Shi M[15] ; Xu L M[16] ; Su H[17] ; Song Y Q[18] ; Zhu J[18] ; Zhang Y J[19] ; Huang H[19] ; Wang Y[20] ; Li Y X[1] ;
机构： [1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [2]Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China. [3]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [4]Department of Radiation Oncology, The General Hospital of Chinese People's Liberation Army, Beijing, China. [5]Beijing Hospital, National Geriatric Medical Center, Beijing, China. [6]The Affiliated Provincial Hospital of Anhui Medical University, Hefei, China. [7]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. [8]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [9]Jiang Xi Province Cancer Hospital, Nanchang, China. [10]Zhejiang Cancer Hospital, Hangzhou, China. [11]The University of Texas MD Anderson Cancer Center, Houston, TX. [12]Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China. [13]Department of Lymphoma, Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, China. [14]Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China. [15]Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. [16]Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, China. [17]Department of Oncology, 307 Hospital, Academy of Military Medical Science, Beijing, People's Republic of China, Beijing, China. [18]Peking University Cancer Hospital & Institute, Beijing, China. [19]Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. [20]Department of Radiation Center, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China.
出处：
DOI： 10.1016/j.ijrobp.2021.07.947
ISSN：

摘要：
This study evaluated the survival benefit of asparaginase (ASP)-based versus non-ASP-based regimens in a real-world cohort of patients with early-stage extranodal nasal-type NK/T-cell lymphoma (ENKTCL).In the modern era, we identified 376 patients who received combined radiotherapy with either ASP-based (asparaginase, platinum and gemcitabine, n = 286) or non-ASP-based (platinum and gemcitabine, n = 90) regimens. The patients were stratified into low-, intermediate- and high-risk groups using the early stage-adjusted nomogram-revised risk index (ES-NRI). Overall survival (OS) and distant metastasis (DM)-free survival (DMFS) between the chemotherapy regimens were compared using inverse probability of treatment weighting (IPTW) and multivariable analyses.ASP-based (versus non-ASP-based) regimens significantly improved 5-year OS (84.5% vs. 73.2%, P = 0.021) and DMFS (84.4% vs. 74.5%, P = 0.014) for intermediate- and high-risk patients, but not for low-risk patients. Moreover, ASP-based regimens decreased DM, with 5-year cumulative DM rate of 14.9% for ASP-based regimens compared with 25.1% (P = 0.014) for non-ASP-based regimens. The survival benefit of ASP-based regimens remained consistent after adjusting the confounding variables by IPTW and multivariate analyses. Additional sensitivity analyses confirmed these results.These findings provide an evidence supporting ASP-based regimens as a first-line combined-modality treatment for intermediate- and high-risk early-stage ENKTCL.Copyright © 2021. Published by Elsevier Inc.

语种：
外文
WOS：
PubmedID：
中科院分区：
出版当年[2021]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 核医学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学 2 区 核医学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2023]版：
Q1 ONCOLOGY Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
推荐引用方式(GB/T 7714)：
Zheng X,He X,Yang Y,et al.Improved Overall Survival Associated With Decreased Distant Metastasis Following Asparaginase-Based Chemotherapy and Radiotherapy for Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma.[J].INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS.2021,111(3):E301-E302.doi:10.1016/j.ijrobp.2021.07.947.
APA：
Zheng X,He X,Yang Y,Qi S N,Zhang L L...&Li Y X.(2021).Improved Overall Survival Associated With Decreased Distant Metastasis Following Asparaginase-Based Chemotherapy and Radiotherapy for Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma..INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS,111,(3)
MLA：
Zheng X,et al."Improved Overall Survival Associated With Decreased Distant Metastasis Following Asparaginase-Based Chemotherapy and Radiotherapy for Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma.".INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 111..3(2021):E301-E302

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号